Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer

Inclusion Criteria

• •Criteria:
• •Histologically or cytologically confirmed renal cell carcinoma
• •Metastatic or unresectable disease
• •Must have received prior sunitinib malate or sorafenib tosylate for metastatic or unresectable disease
• •Measurable disease
• •No soft tissue disease that has been irradiated within the past 2 months
• •More than 6 months since prior and no concurrent treated or untreated brain metastases
• •Stable, treated brain metastases allowed provided they remained stable for more than 6 months
• •Patients with clinical evidence of brain metastases must have a negative brain CT or MRI scan for metastatic disease
• •Zubrod performance status 0-1
• •Urine protein:creatinine ratio =\< 0.5 OR urine protein \< 1,000 mg by 24-hour collection
• •Not be pregnant or nursing
• •Fertile patients must use effective contraception during and for at least 6 months after completion of study therapy
• •No serious or non-healing wound, ulcer, or bone fracture
• •No clinically relevant bleeding diathesis or coagulopathy
• •No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days
• •No significant traumatic injury within the past 28 days
• •No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
• •No other prior malignancy, except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years
• •No New York Heart Association class II-IV congestive heart failure
• •No unstable symptomatic arrhythmia requiring medication
• •Chronic, controlled arrhythmias (e.g., atrial fibrillation or paroxysmal supraventricular tachycardia) allowed
• •None of the following cardiovascular conditions within the past 6 months: Arterial thrombosis, Unstable angina, Myocardial infarction, Cerebrovascular accident
• •Must have controlled blood pressure, defined as systolic blood pressure (BP) =\< 160 mm Hg and/or diastolic BP =\< 90 mm Hg
• •More than 7 days since prior core biopsy
• •At least 14 days since completion of prior therapy and recovered
• •At least 28 days since prior radiotherapy and recovered
• •No prior radiotherapy to \>= 25% of bone marrow
• •No more than two prior systemic regimens for renal cell carcinoma (including adjuvant treatment)
• •No prior bevacizumab or humanized monoclonal antibody MEDI-522
• •No major surgical procedure or open biopsy within the past 28 days
• •No concurrent need for a major surgical procedure
• •Concurrent full-dose anticoagulation with warfarin allowed provided INR is between 2-3
• •Concurrent low molecular weight heparin allowed
• •No clinically significant vascular disease (e.g., aortic aneurysm or history of aortic dissection)